835 related articles for article (PubMed ID: 18678491)
1. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of curcumin analogues.
Fuchs JR; Pandit B; Bhasin D; Etter JP; Regan N; Abdelhamid D; Li C; Lin J; Li PK
Bioorg Med Chem Lett; 2009 Apr; 19(7):2065-9. PubMed ID: 19249204
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity.
Liu Z; Huang SL; Li MM; Huang ZS; Lee KS; Gu LQ
Chem Biol Interact; 2009 Jan; 177(1):48-57. PubMed ID: 18822278
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of thioredoxin reductase by curcumin analogs.
Liu Z; Du ZY; Huang ZS; Lee KS; Gu LQ
Biosci Biotechnol Biochem; 2008 Aug; 72(8):2214-8. PubMed ID: 18685195
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof.
Yamakoshi H; Ohori H; Kudo C; Sato A; Kanoh N; Ishioka C; Shibata H; Iwabuchi Y
Bioorg Med Chem; 2010 Feb; 18(3):1083-92. PubMed ID: 20060305
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy.
He J; Li D; Xiong K; Ge Y; Jin H; Zhang G; Hong M; Tian Y; Yin J; Zeng H
Bioorg Med Chem; 2012 Jun; 20(12):3816-27. PubMed ID: 22579620
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of 5-nitro-2-furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors.
Millet R; Urig S; Jacob J; Amtmann E; Moulinoux JP; Gromer S; Becker K; Davioud-Charvet E
J Med Chem; 2005 Nov; 48(22):7024-39. PubMed ID: 16250662
[TBL] [Abstract][Full Text] [Related]
8. Natural product based inhibitors of the thioredoxin-thioredoxin reductase system.
Wipf P; Lynch SM; Birmingham A; Tamayo G; Jiménez A; Campos N; Powis G
Org Biomol Chem; 2004 Jun; 2(11):1651-8. PubMed ID: 15162219
[TBL] [Abstract][Full Text] [Related]
9. 2a, a novel curcumin analog, sensitizes cisplatin-resistant A549 cells to cisplatin by inhibiting thioredoxin reductase concomitant oxidative stress damage.
Zhou B; Huang J; Zuo Y; Li B; Guo Q; Cui B; Shao W; Du J; Bu X
Eur J Pharmacol; 2013 May; 707(1-3):130-9. PubMed ID: 23524096
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system.
Wipf P; Lynch SM; Powis G; Birmingham A; Englund EE
Org Biomol Chem; 2005 Nov; 3(21):3880-2. PubMed ID: 16240002
[TBL] [Abstract][Full Text] [Related]
11. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of aromatic enones related to curcumin.
Robinson TP; Hubbard RB; Ehlers TJ; Arbiser JL; Goldsmith DJ; Bowen JP
Bioorg Med Chem; 2005 Jun; 13(12):4007-13. PubMed ID: 15911313
[TBL] [Abstract][Full Text] [Related]
13. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents.
Liang G; Shao L; Wang Y; Zhao C; Chu Y; Xiao J; Zhao Y; Li X; Yang S
Bioorg Med Chem; 2009 Mar; 17(6):2623-31. PubMed ID: 19243951
[TBL] [Abstract][Full Text] [Related]
14. Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.
Ai Y; Zhu B; Ren C; Kang F; Li J; Huang Z; Lai Y; Peng S; Ding K; Tian J; Zhang Y
J Med Chem; 2016 Mar; 59(5):1747-60. PubMed ID: 26891099
[TBL] [Abstract][Full Text] [Related]
15. Oxiranylmethyloxy or thiiranylmethyloxy-azaxanthones and -acridone analogues as potential topoisomerase I inhibitors.
Cho HJ; Jung MJ; Kwon Y; Na Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6766-9. PubMed ID: 19836231
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
17. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity.
Chew EH; Lu J; Bradshaw TD; Holmgren A
FASEB J; 2008 Jun; 22(6):2072-83. PubMed ID: 18180330
[TBL] [Abstract][Full Text] [Related]
18. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
Wang X; Zhang J; Xu T
Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
